2. Division of Diabetes Translation Office of the Director Director: Ann Albright, Ph.D., R.D. Deputy Director: Angela Green-Phillips, M.P.A. Associate Director for Science: Lawrence Barker, Ph.D Policy and Program Information Team Team Lead: Karen Richard-Lee, M.P.A. Communication & Partnership Team Team Lead: Laura Zauderer, M.P.H. Health Disparities Coordination Coordinator: Regina Hardy, B.A., M.S. Primary Prevention Initiative Team Program and Policy Coordinator: Russell Sniegowski, M.P.H. Senior Science Consultant: David F. Williamson, Ph.D. Administrative Services Administrative Officer: Bonita Foley Epidemiology and Statistics Branch Branch Chief: Edward Gregg, Ph.D. Associate Branch Chief: Desmond Williams, M.D., Ph.D. Native Diabetes Wellness Program (NDWP) Team Lead: Dawn Satterfield, R.N., Ph.D. National Diabetes Education Program (NDEP) Director: Judith McDivitt, Ph.D. Deputy Director: Betsy Rodriguez, B.S.N., M.S.N. Evaluation Team Acting Team Lead: Barbara Park, R.D.H., M.P.H. State Consultation Team Senior Team Lead: Patricia Schumacher, M.S., R.D. Team Lead: Andy Lanza, M.P.H., M.S.W. Team Lead: Wayne Millington, M.P.A. Epidemiology Team Team Lead: Guissepina Imperatore, M.D., Ph.D. Economics Team Team Lead: Ping Zhang, Ph.D. Surveillance Team Team Lead: Linda Geiss, M.A. Vision Health Team Team Lead: Jinan Saaddine, M.D., M.P.H. Statistics Team Team Lead: Ted Thompson, M.S. Chronic Kidney Disease Team Team Lead: Desmond Williams, M.D., Ph.D. CS205388-A Program Admin Coordination (PAC) Team Team Lead: Patricia Mitchell, M.P.H. Program and Evaluation Branch Branch Chief: Barbara Park, R.D.H., M.P.H. Deputy Branch Chief: Patricia Mitchell, M.P.H.

3. DDT Strategic Plan Goals  Prevent diabetes  Prevent complications, disabilities and burden associated with diabetes  Eliminate diabetes-related health disparities  Maximize organizational capability to achieve goals Build capacity for communication, evaluation, marketing, policy, and partnerships Create and implement mgmt plan for leadership development, workforce development, and diversity  Prevent diabetes  Prevent complications, disabilities and burden associated with diabetes  Eliminate diabetes-related health disparities  Maximize organizational capability to achieve goals Build capacity for communication, evaluation, marketing, policy, and partnerships Create and implement mgmt plan for leadership development, workforce development, and diversity

4. Division of Diabetes Translation  Tracking the disease burden  Conducting applied translation research to prioritize effective interventions  Economic analyses  Developing and maintaining state-based diabetes prevention and control programs  Implementing National Program Initiatives:  National Diabetes Education Program  Native Diabetes Wellness Program  Tracking the disease burden  Conducting applied translation research to prioritize effective interventions  Economic analyses  Developing and maintaining state-based diabetes prevention and control programs  Implementing National Program Initiatives:  National Diabetes Education Program  Native Diabetes Wellness Program

5. Diabetes Prevention and Control Programs 50 States & DC 8 Territories 17 Tribes Vulnerable Pops

6. National Diabetes Education Program* *NDEP is a joint initiative of CDC and NIH

7. Using Core Public Health Functions and the 10 Essential Public Health Services The Role of DPCP’s Partnership Development Assessment & Strategic Planning Quality Care Improvement Diabetes Surveillance Raising the Profile of Diabetes Workforce Development Technical Assistance

8. Surveillance Observational and Clinical Epidemiology Health Services And Policy Research Economic and Cost- Effectiveness Research National Surveillance System Risk Factors Prevalence / Incidence Complications Care and treatment Small Area Methods SEARCH Modeling / Forecasting Vision Health Initiative (VHI) CKD Program Cost- effectiveness Studies DPP-OS Look AHEAD ACCORD Vision Health Initiative Chronic Kidney Disease Program Lifestyle Interventions Body Composition Risk Identification tools Da Qing Follow-up NIH Collaborative Trials SES Disparities Life stages (youth / aging) Modeling / Forecasting TRIAD Study NDSS VH Initiative CKD Program Access to care

9. Vital statistics Household Surveys Registries Hospitals CDC National Diabetes Surveillance System Telephone Surveys

10. Analytic Applications of U.S. National Diabetes Surveillance System  Characterizing diabetes epidemic, its risk factors and impact.  Identifying key at-risk populations.  Modeling the disease and cost impact over time and lifetime.  Setting and monitoring national health objectives.  Investigating new threats.  National Diabetes Fact Sheet  Characterizing diabetes epidemic, its risk factors and impact.  Identifying key at-risk populations.  Modeling the disease and cost impact over time and lifetime.  Setting and monitoring national health objectives.  Investigating new threats.  National Diabetes Fact Sheet

11. Small Area Estimates

12. Effectiveness Studies  NEXT-D (Natural Experiments in Translation for Diabetes)  Da Qing Follow-up Study  U.S. Mexico Border Project  TRIAD (Translating Research into Action for Diabetes)  Diabetes Prevention Program (DPPOS)  Look AHEAD Study  ACCORD Study  NEXT-D (Natural Experiments in Translation for Diabetes)  Da Qing Follow-up Study  U.S. Mexico Border Project  TRIAD (Translating Research into Action for Diabetes)  Diabetes Prevention Program (DPPOS)  Look AHEAD Study  ACCORD Study

13. New Research Initiatives  NEXT-D (Natural Experiments in Translation for Diabetes)  Vision Health Initiative Translation Research Centers  Advances in Surveillance Small Area State-based Incidence  Revised Disease Forecasting Incidence Cost Intervention Effectiveness  National Primary Prevention registry and evaluation  NEXT-D (Natural Experiments in Translation for Diabetes)  Vision Health Initiative Translation Research Centers  Advances in Surveillance Small Area State-based Incidence  Revised Disease Forecasting Incidence Cost Intervention Effectiveness  National Primary Prevention registry and evaluation

14. Natural Experiments and Effectiveness Studies of Population-Targeted Policies for Diabetes Prevention and Control  The Diabetes Health Plan: A System-Level Intervention to Prevent and Treat Diabetes University of California Los Angeles Principal Investigator: Dr. Carol Mangione  Effectiveness of a National Health Care Community Partnership to Prevent Diabetes Indiana University Principal Investigator: Dr. Ron Ackermann  The Impact of Emerging Health Insurance Designs on Diabetes Outcomes and Disparities Harvard Pilgrim Health Care and Harvard University Principal Investigator: Dr. Dennis Ross-Degnan  Learnings in Diabetes Prevention from an Integrated Delivery System Kaiser Foundation Research Institute Principal Investigator: Dr. Joe Selby  Management and Education for Diabetes in New York City St. Luke’s-Roosevelt Institute for Health Sciences Principal Investigator: Dr. Jeanine Albu  The Diabetes Health Plan: A System-Level Intervention to Prevent and Treat Diabetes University of California Los Angeles Principal Investigator: Dr. Carol Mangione  Effectiveness of a National Health Care Community Partnership to Prevent Diabetes Indiana University Principal Investigator: Dr. Ron Ackermann  The Impact of Emerging Health Insurance Designs on Diabetes Outcomes and Disparities Harvard Pilgrim Health Care and Harvard University Principal Investigator: Dr. Dennis Ross-Degnan  Learnings in Diabetes Prevention from an Integrated Delivery System Kaiser Foundation Research Institute Principal Investigator: Dr. Joe Selby  Management and Education for Diabetes in New York City St. Luke’s-Roosevelt Institute for Health Sciences Principal Investigator: Dr. Jeanine Albu

15. Policies and Interventions Proposed in Phase I Studies  Employer-based detection, outreach, incentives, and telephone coaching for primary prevention among 3750 high risk adults from 5 employers.  Disease-specific health insurance product; reduced copayments, and incentives among 136,000.  Impact of reduced copayments and incentives among adults with diabetes and pre-diabetes from 15 large employers.  Systematic post-partum screening of women with GDM.  Employer-based detection, outreach, incentives, and telephone coaching for primary prevention among 3750 high risk adults from 5 employers.  Disease-specific health insurance product; reduced copayments, and incentives among 136,000.  Impact of reduced copayments and incentives among adults with diabetes and pre-diabetes from 15 large employers.  Systematic post-partum screening of women with GDM.

16. Policies and Interventions Proposed in Phase I Studies  Enhanced EMR with decision support for diabetes care, screening, and prevention referral among 4000 adults with DM and pre-DM;  Impact of employer-mandated switch to high deductible and “consumer- driven” health plans among 62,000 diabetic adults age 18-64.  Health plan administered diabetes prevention programs delivered in YMCAs on 7500 high risk adults.  Pre-diabetes screening and referral to multi-tiered interventions.  Enhanced EMR with decision support for diabetes care, screening, and prevention referral among 4000 adults with DM and pre-DM;  Impact of employer-mandated switch to high deductible and “consumer- driven” health plans among 62,000 diabetic adults age 18-64.  Health plan administered diabetes prevention programs delivered in YMCAs on 7500 high risk adults.  Pre-diabetes screening and referral to multi-tiered interventions.

17.  Population targeted policies and interventions from 3 sources: Health Systems; Business and community organizations; Government agencies  Ongoing or imminent interventions with cost of intervention underwritten by other sources.  Aimed at prevention of diabetes and/or its complications.  Population targeted policies and interventions from 3 sources: Health Systems; Business and community organizations; Government agencies  Ongoing or imminent interventions with cost of intervention underwritten by other sources.  Aimed at prevention of diabetes and/or its complications. Attributes of Studies

20. Primary Funding Mechanisms  Grants  Cooperative Agreements  Contracts  State DPCPs  Grants  Cooperative Agreements  Contracts  State DPCPs